Send us a text Obesity presents a persistent challenge in the management of cancer-associated thrombosis, particularly when prescribing low molecular weight heparin beyond standard dose caps. In this episode of CLOT Conversations, host Dr. Jameel Abdulrehman is joined by Dr. Tzu-Fei Wang and Dr. Grégoire Le Gal to discuss findings from the WAVe study, a multicenter prospective cohort study evaluating weight-adjusted dalteparin dosing in patients over 90 kg with acute cancer-associated venous ...
All content for CLOT Conversations is the property of Thrombosis Canada and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text Obesity presents a persistent challenge in the management of cancer-associated thrombosis, particularly when prescribing low molecular weight heparin beyond standard dose caps. In this episode of CLOT Conversations, host Dr. Jameel Abdulrehman is joined by Dr. Tzu-Fei Wang and Dr. Grégoire Le Gal to discuss findings from the WAVe study, a multicenter prospective cohort study evaluating weight-adjusted dalteparin dosing in patients over 90 kg with acute cancer-associated venous ...
Send us a text In this episode we speak with the three competitors from the INVENT Dragons' Den competition 2025. Hear from the researchers about their research plans that they presented in the hopes of being awarded $40,000 in funding. The researchers were: Dr Francis Couturaud (ETHER Study), Dr Leslie Skeith (PARTUM Study) and Dr Emma Leitinger (BUTTERFLY Study). Participating INVENT network members include CanVECTOR (Canada), CURES Network (China), INNOVTE (France), INViTE (Ireland), DTN (...
CLOT Conversations
Send us a text Obesity presents a persistent challenge in the management of cancer-associated thrombosis, particularly when prescribing low molecular weight heparin beyond standard dose caps. In this episode of CLOT Conversations, host Dr. Jameel Abdulrehman is joined by Dr. Tzu-Fei Wang and Dr. Grégoire Le Gal to discuss findings from the WAVe study, a multicenter prospective cohort study evaluating weight-adjusted dalteparin dosing in patients over 90 kg with acute cancer-associated venous ...
